Invitris

Creating new protein-based drugs at scale

Based based in Munich, BY, Germany, Invitris works in healthcare, founded in 2022.

Profile

Invitris radically simplifies how we create novel biological drugs. Our patent-pending technology platform turns DNA into synthetic proteins and was recently featured in the Science magazine. It makes creating new drugs >10,000x more efficient at <100x lower costs of material.

Our killer application is enabling the newest generation of synthetic bacteriophages to combat antibiotic-resistant infections, which are threatening to cause more deaths than all cancers combined.

Invitris is positioned in healthcare, a segment that rewards a clear, focused offering.

Its base of operations is Munich, BY, Germany.

Directory data places it at the Winter 2023 stage.

Recorded headcount: 6 employees.

Public records show total funding of about $5K.

Website: invitris.com